share_log

CardioComm Solutions, Inc. Secures Exclusive Distribution Rights in Quebec for ECG Medical Devices

CardioComm Solutions, Inc. Secures Exclusive Distribution Rights in Quebec for ECG Medical Devices

CardioComm Solutions, Inc.已獲得ECG醫療設備在魁北克的獨家分銷權
newsfile ·  08/28 18:04

Deal enhances access to long term continuous ECG monitoring devices for Canadians

該協議增加了加拿大人獲得長期持續心電圖監測設備的機會

Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software and hardware solutions, is pleased to announce an exclusivity agreement for the Province of Quebec for the sale and distribution of TZ Medical Inc. ("TZM") ECG monitoring devices used for standard and extended Holter and cardiac arrhythmia monitoring.

安大略省多倫多--(Newsfile Corp.,2024年8月28日)——消費者心臟監測和醫用心電圖(「ECG」)軟件和硬件解決方案的全球醫療提供商CardioComm Solutions, Inc.(多倫多證券交易所股票代碼:EKG)(「CardioComm」 或 「公司」)很高興地宣佈魁北克省簽訂獨家銷售和分銷TZ Medical Inc.(「TZM」”) 心電監護設備用於標準和延長 Holter 和心律失常監測。

CardioComm has had a long-standing relationship with the hardware manufacturer, Oregon-based TZM, and is a non-exclusive distributor for TZM's ECG monitoring medical devices in Canada and the US. Of specific interest are the TZM Trident Pro and Trident Nano devices that are integrated with CardioComm's class-leading Global Electrocardiogram Management software (GEMSTM), which is widely licensed by North American clinics and hospitals. The addition of Quebec exclusivity will facilitate hardware tendering processes with provincial hospitals that use or are considering a license for use of GEMSTM.

CardioComm與硬件製造商總部位於俄勒岡州的TzM有着長期的合作關係,並且是TZM心電監測醫療設備在加拿大和美國的非獨家分銷商。特別令人感興趣的是TzM Trident Pro和Trident Nano設備,它們集成了CardioComm一流的全球心電圖管理軟件(GEMSTM),該軟件已獲得北美診所和醫院的廣泛許可。魁北克獨家經營權的增加將促進使用或正在考慮獲得GemstM使用許可證的省級醫院的硬件招標流程。

CardioComm will integrate the TZM Trident Pro and Nano devices with GEMSTM Holter and GEMS Long Term Continuous Monitoring (GEMS LTCM), two new CardioComm software releases planned for 2025. CardioComm's GEMS LTCM will be positioned to meet the growing demand for combined, 14 to 30 day, Holter and Event monitoring. The new devices will join CardioComm's growing product lines, including the HeartCheckTM branded home ECG devices, the Body-by-GEMSTM multiple bio-signal monitoring solutions, and the GEMSTM-based products for clinics and hospitals.

CardioComm將把tzM Trident Pro和Nano設備與GemsTM Holter和GEMS長期持續監測(GEMS LTCM)整合在一起,這兩個新的CardioComm軟件計劃於2025年發佈。CardioComm的GEMS LTcm將有能力滿足對14至30天動態心電和事件綜合監測不斷增長的需求。這些新設備將加入CardioComm不斷增長的產品線,包括HeartcheckTM品牌的家用心電圖設備、Body-by-GemstM多種生物信號監測解決方案以及基於Gemstm的診所和醫院產品。

To learn more about CardioComm's products and for further updates please visit the Company's websites at and .

要了解有關CardioComm產品的更多信息以及進一步的更新,請訪問公司的網站和。

About CardioComm Solutions

關於 CardioComm 解決方案

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).

CardioComm Solutions的專利專有技術用於記錄、查看、分析和存儲心電圖的產品,用於心臟病患者的診斷和管理。產品通過外部分銷網絡和北美銷售團隊的組合在全球範圍內銷售。CardioComm Solutions已獲得ISO 13485和ISO 27001認證,符合HIPAA標準,並持有美國(FDA)和加拿大(加拿大衛生部)的醫療器械許可和銷售許可證。

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com

欲了解更多信息,請聯繫:
首席執行官艾蒂安·格里瑪
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com

Forward-looking statements

前瞻性陳述

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

本新聞稿可能包含與CardioComm Solutions的財務狀況、經營業績和業務以及CardioComm Solutions在這些項目上的某些計劃和目標有關的某些前瞻性陳述和前瞻性信息。此類陳述和信息反映了管理層當前的信念,並基於管理層目前獲得的信息。就其性質而言,前瞻性陳述和前瞻性信息涉及風險和不確定性,因爲它們與事件有關並取決於未來發生的情況,而且有許多因素可能導致實際業績和發展與這些前瞻性陳述和前瞻性信息所表達或暗示的結果和暗示存在重大差異。

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

在評估這些陳述時,讀者不應過分依賴前瞻性陳述和前瞻性信息。除適用法律(包括但不限於National Instrument 51-102第5.8(2)條(持續披露義務)要求外,公司不承擔更新本新聞稿中包含的前瞻性陳述和前瞻性信息的任何義務。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險投資交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論